NovoSeven

Type: Product
Name: NovoSeven
First reported 6 hours ago - Updated 6 hours ago - 1 reports

The new oral anticoagulants and management of bleeding

April 2014 Volume 21, Issue 2 (online first) Br J Cardiol 2014;21:(2) Authors:Raza AlikhanAtrial fibrillation (AF) is the most common sustained arrhythmia faced by clinicians in primary and secondary care. Patients with AF face a significant risk of stroke ... [Published British Journal of Cardiology - 6 hours ago]
First reported Apr 21 2014 - Updated Apr 21 2014 - 1 reports

The price is right for patient-switching on Biogen's new hemophilia med Alprolix

With a pair of long-acting hemophilia meds on the way, Biogen Idec ($BIIB) appears poised to shake up the market for the bleeding disease. And though recently approved Alprolix has yet to launch, it has already made waves: Biogen has priced it on par ... [Published FiercePharma - Apr 21 2014]
First reported Apr 16 2014 - Updated Apr 16 2014 - 1 reports

PharmaPoint: Hemophilia A and B - US Drug Forecast and Market Analysis to 2022

04/16 14:43 CDT LONDON, April 16, 2014LONDON, April 16, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:PharmaPoint: Hemophilia A and B - US Drug Forecast and Market Analysis to 2022http://www.reportbuyer.com/pharma_healthcare/diseases/pharmapoint_hemophilia ... [Published Finwin - Apr 16 2014]
First reported Apr 02 2014 - Updated Apr 03 2014 - 1 reports

Biogen's Alprolix nod is just the first tremor in a hemophilia market shake-up

New, long-acting hemophilia therapies are preparing to take the market by storm. For patients, they'll require less frequent infusions, proving more convenient. But for current market leaders like Baxter International ($BAX), they could put millions in ... [Published FiercePharma - Apr 02 2014]
First reported Mar 31 2014 - Updated Apr 01 2014 - 1 reports

Biogen hemophilia nod puts Baxter's to-be-spun-off biopharma unit on notice

Biogen Idec now has FDA approval for Alprolix, the first in a new wave of long-acting hemophilia treatments on their way to market. For Biogen ($BIIB), the thumbs-up is an opportunity to grab market share with a hemophilia B product that works three times ... [Published FiercePharma - Mar 31 2014]
First reported Mar 19 2014 - Updated Mar 20 2014 - 1 reports

Positive Ph III results with Novo Nordisk’s N8-GP, a long-acting hemophilia A agent

Danish insulin giant Novo Nordisk (NOV: N) says it has completed the pathfinderT2, the first Phase III trial with long-acting recombinant factor VIII, N8-GP (turoctocog alfa pegol) for hemophilia A patients.PathfinderT2 is a multi-national trial evaluating ... [Published Pharma Letter - Mar 19 2014]
First reported Feb 03 2014 - Updated Feb 03 2014 - 1 reports

Human medicines European public assessment report (EPAR): NovoSeven, eptacog alfa (activated), Revision: 28, Authorised

Entities: NovoSeven
First reported Jan 31 2014 - Updated Jan 31 2014 - 1 reports

Research and Markets: Novoseven RT (Hemophilia A and B) - Forecast and Market Analysis to 2022 Research Report

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/mf7sbv/novoseven_rt) has announced the addition of the "Novoseven RT (Hemophilia A and B) - Forecast and Market Analysis to 2022" report to their offering. The competitive ... [Published Business Wire Professional Services News - Jan 31 2014]

Quotes

"In essence, Biogen appears to be more focused on getting the patient switches" ISI Group analyst Mark Schoenebaum wrote in a note to investors about the pricing strategy
...in time … we would think that the field would move over to the use of products that last longer and decrease the burden of therapy," Pierce said. "Why would you use something two to three times a week if you could use something much less frequently, assuming it has the same safety profile? These are intravenous injections--they're tough. Patients do them themselves."
Still, as always, the size of Baxter's hit will depend on patient preferences and loyalty to current treatments. "They may opt for convenience one day, but what they'll do over the next few years can be different" Miksic told the Journal
"We are very pleased with the results of pathfinderT2. These results show that N8-GP has the potential to reduce the burden of treatment by decreasing the number of intravenous infusions while achieving strong results in terms of efficacy and safety for people with hemophilia A" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk

More Content

All (9) | News (6) | Reports (0) | Blogs (2) | Audio/Video (0) | Fact Sheets (1) | Press Releases (0)
sort by: Date | Relevance
The new oral anticoagulants and management of b... [Published British Journal of Cardiology - 6 hours ago]
The price is right for patient-switching on Bio... [Published FiercePharma - Apr 21 2014]
PharmaPoint: Hemophilia A and B - US Drug Forec... [Published Finwin - Apr 16 2014]
Biogen's Alprolix nod is just the first tremor ... [Published FiercePharma - Apr 02 2014]
Biogen hemophilia nod puts Baxter's to-be-spun-... [Published FiercePharma - Mar 31 2014]
Positive Ph III results with Novo Nordisk’s N8-... [Published Pharma Letter - Mar 19 2014]
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Feb 03 2014]
Research and Markets: Novoseven RT (Hemophilia ... [Published Business Wire Professional Services News - Jan 31 2014]
Fact Sheet for Novo-Nordisk A/S [Published Able2Act - Jul 24 2008]
1
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Feb 03 2014]
Research and Markets: Novoseven RT (Hemophilia ... [Published Business Wire Professional Services News - Jan 31 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/mf7sbv/novoseven_rt) has announced the addition of the "Novoseven RT (Hemophilia A and B) - Forecast and Market Analysis to 2022" report to their offering. The competitive ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.